NCT02684227 - Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2016

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions

Recurrent Endometrial Endometrioid AdenocarcinomaRecurrent Uterine Corpus CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IIIA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7Stage IVA Uterine Corpus Cancer AJCC v7Stage IVB Uterine Corpus Cancer AJCC v7

Interventions

DRUG

Carboplatin

Given IV

DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (6)

77030

M D Anderson Cancer Center, Houston

77054

The Woman's Hospital of Texas, Houston

77058

MD Anderson League City, Nassau Bay

77094

MD Anderson in Katy, Houston

77384

MD Anderson in The Woodlands, The Woodlands

77478

MD Anderson in Sugar Land, Sugar Land

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER